pSivida to Present at Canaccord Genuity Growth Conference on August 10, 2017
August 01 2017 - 7:00AM
pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development
of ocular sustained release drug products and technologies for eye
diseases, today announced that Nancy Lurker, President and Chief
Executive Officer, will present at the Canaccord Genuity 2017
Growth Conference at the InterContinental Boston in Boston, MA. The
presentation is scheduled for Thursday, August 10, 2017, at 2:30pm
Eastern Time.
A live audio and/or webcast and subsequent archived
replay of pSivida’s presentation may be accessed via the Investors
section of the Company’s website under “Resources - Events &
Presentations” at www.psivida.com. The replay will be available for
90 days after the event.
About pSivida Corp.pSivida
Corp. (www.psivida.com), headquartered in Watertown, MA, is a
leader in the development of sustained release drug for eye
diseases. pSivida has developed three of only four FDA-approved
sustained-release treatments for back-of-the-eye diseases. The most
recent, ILUVIEN®, a micro-insert for diabetic macular edema,
licensed to Alimera Sciences, is currently sold in the US and three
EU countries. Retisert®, an implant for posterior uveitis, is
licensed to and sold by Bausch & Lomb. pSivida's lead product
candidate, Durasert micro-insert for posterior segment uveitis
being independently developed. Two pivotal Phase 3 studies achieved
their primary efficacy endpoint at six months of follow-up with
statistical significance. pSivida's pre-clinical development
program is focused on using its core platform technology Durasert™
to deliver drugs and biologics to treat uveitis, wet age-related
macular degeneration, osteoarthritis and other diseases. To learn
more about pSivida, please visit www.psivida.com and connect on
Twitter, LinkedIn, Facebook and Google+.
Contact:
EVC Group
Michael Polyviou/Doug Sherk – Investors
mpolyviou@evcgroup.com; dsherk@evcgroup.com
212.850.6020; 646-445-4800
Thomas Gibson – Media
tom@tomgibsoncommunications.com
201-476-0322
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
From Apr 2023 to Apr 2024